You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 8, 2025

Drug Price Trends for TRAVOPROST


✉ Email this page to a colleague

« Back to Dashboard


Drug Price Trends for TRAVOPROST

Average Pharmacy Cost for TRAVOPROST

These are average pharmacy acquisition costs (net of discounts) from a US national survey
Drug Name NDC Price/Unit ($) Unit Date
TRAVOPROST 0.004% EYE DROP 70069-0586-01 14.48089 ML 2025-02-05
TRAVOPROST 0.004% EYE DROP 70069-0587-01 15.23827 ML 2025-02-05
TRAVOPROST 0.004% EYE DROP 00378-9651-32 14.48089 ML 2025-01-22
TRAVOPROST 0.004% EYE DROP 00378-9651-50 15.23827 ML 2025-01-22
>Drug Name >NDC >Price/Unit ($) >Unit >Date

Best Wholesale Price for TRAVOPROST

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available to any customer under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Unit Dates Price Type
TRAVOPROST 0.004% SOLN,OPH Sandoz, Inc. 00781-6185-56 2.5ML 18.54 7.41600 ML 2024-01-01 - 2028-08-14 FSS
TRAVOPROST 0.004% SOLN,OPH Sandoz, Inc. 00781-6185-75 5ML 37.13 7.42600 ML 2023-08-15 - 2028-08-14 FSS
TRAVATAN Z 0.004% SOLN Sandoz, Inc. 00078-0946-25 5ML 292.39 58.47800 ML 2023-09-29 - 2028-08-14 FSS
TRAVOPROST 0.004% SOLN,OPH Sandoz, Inc. 00781-6185-75 5ML 28.37 5.67400 ML 2024-01-01 - 2028-08-14 FSS
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Unit >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Market Analysis and Price Projections for Travoprost

Introduction to Travoprost

Travoprost is a potent FP receptor agonist used as an ocular hypotensive agent for the treatment of glaucoma and ocular hypertension. It is part of the prostaglandin analog class of drugs, which are widely used to reduce intraocular pressure.

Market Size and Growth Projections

The global Travoprost market is anticipated to experience significant growth over the next few years, driven by several key factors.

  • Global Market Value: The Travoprost market was valued at USD 0.80 billion in 2022 and is projected to reach USD 1.25 billion by 2030, growing at a CAGR of 6.5% from 2024 to 2030[3].
  • Regional Growth: The North American region holds the largest market share due to the high prevalence of glaucoma and the presence of major pharmaceutical companies. The Asia-Pacific region, particularly countries like India and China, is expected to witness significant growth due to increasing awareness of glaucoma and rising healthcare expenditures[1][4].

Key Drivers of Market Growth

Several factors are driving the growth of the Travoprost market:

  • Increasing Prevalence of Glaucoma: The rising incidence of glaucoma, especially in aging populations, is a major driver. As the global population ages, the demand for effective treatments like Travoprost is expected to increase[1][3][4].
  • Advancements in Drug Delivery Systems: Innovations in drug delivery, such as microemulsion formulations and sustained-release systems, are enhancing the efficacy and convenience of Travoprost, driving market growth[3].
  • Expanding Healthcare Access: Initiatives to expand healthcare access and affordability, particularly in emerging economies, are contributing to the market's growth[1][3].
  • Technological Innovations: Technological advancements, including automation and AI in healthcare, are further boosting the market by improving operational efficiency and reducing environmental impact[2].

Competitive Landscape

The Travoprost market is highly competitive with both established and emerging players.

  • Key Players: Major companies in the market include Cayman Pharma, FCAD, SALVAVIDAS PHARMACEUTICAL, Tecoland, HBCChem, Alfa Chemistry, Hangzhou Keying Chem, Sinoway Industrial, Taizhou Volsen Chemical, and Eastar. These companies are focusing on developing innovative products, expanding distribution networks, and strengthening R&D capabilities to gain a competitive edge[1][4].
  • Mergers and Acquisitions: The market has witnessed notable M&A activity, with acquisitions and partnerships aimed at expanding product portfolios and enhancing market access. Industry consolidation is expected to continue, particularly in the development of innovative therapies[1].

Market Segmentation

The Travoprost market is segmented based on several criteria:

  • Application: The market is segmented into research, medical, and pharmaceutical applications. The medical segment, particularly glaucoma treatment, accounts for over 80% of total sales[1].
  • Type: The market is segmented by purity levels, including Min Purity Less Than 98%, Min Purity 98%-99%, and Min Purity More Than 99%[1].
  • Region: The market is segmented into North America, Europe, Asia Pacific, South America, and Middle East & Africa. North America holds the largest market share, followed by the Asia-Pacific region[1][4].

Price Projections and Affordability

The cost of Travoprost can vary significantly depending on the region and availability of insurance.

  • Cost Without Insurance: A 30-day supply of Travoprost (one bottle with 2.5 mL of 0.004% ophthalmic solution) averages about $200, or slightly less than $7 per dose. A full year of treatment for both eyes can cost around $2,400[5].
  • Generic and Brand-Name Prices: Generic versions of Travoprost are available at lower prices, such as $50 for a 2.5 mL bottle, compared to brand-name versions like Travatan Z, which can cost around $247 for a similar quantity[5].
  • Savings Options: Various savings options, including discounts and generic alternatives, are available to make Travoprost more affordable for patients[5].

Future Outlook and Challenges

The future of the Travoprost market is promising but also presents several challenges:

  • Technological Advancements: The next decade will see more advanced drug delivery systems, such as microemulsion formulations, making eye drops easier to administer and more effective[3].
  • Generic Competition: With patents for Travoprost expiring, the market is likely to see an increase in generic versions, which may drive prices down but also increase accessibility[3].
  • Expanding Therapeutic Options: New treatments for glaucoma and ocular hypertension could reduce the dominance of Travoprost, but it will remain a key player due to its proven efficacy[3].
  • Growing Awareness in Emerging Markets: As awareness of eye diseases rises in countries like India and China, demand for affordable and effective treatments like Travoprost will grow[3].

Key Takeaways

  • The global Travoprost market is projected to grow significantly, driven by the increasing prevalence of glaucoma and advancements in drug delivery systems.
  • North America holds the largest market share, but the Asia-Pacific region is expected to witness significant growth.
  • The market is highly competitive, with key players focusing on innovation and market expansion.
  • Price variations exist between brand-name and generic versions, with savings options available to make the drug more affordable.
  • Future growth will be influenced by technological advancements, generic competition, and expanding therapeutic options.

FAQs

  1. What is the current market size of the Travoprost market?

    • The Travoprost market was valued at USD 0.80 billion in 2022 and is projected to reach USD 1.25 billion by 2030[3].
  2. What are the key drivers of the Travoprost market growth?

    • The rising incidence of glaucoma, advancements in drug delivery systems, and expanding healthcare access are key drivers[1][3][4].
  3. Who are the major players in the Travoprost market?

    • Major companies include Cayman Pharma, FCAD, SALVAVIDAS PHARMACEUTICAL, Tecoland, HBCChem, Alfa Chemistry, and others[1][4].
  4. How much does Travoprost cost without insurance?

    • A 30-day supply of Travoprost can cost around $200, or slightly less than $7 per dose, without insurance[5].
  5. What are the future challenges and opportunities for the Travoprost market?

    • The market will face challenges from generic competition and new therapeutic options but will benefit from technological advancements and growing awareness in emerging markets[3].

Sources

  1. Data Insights Market: Travoprost Market's Growth Catalysts[1]
  2. GitHub: Travoprost Reagent Market Size And Forecast[2]
  3. GitHub: Travoprost Eye Drops Market Size and Outlook Insights Report[3]
  4. QYResearch: Travoprost - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030[4]
  5. SingleCare: How much is travoprost without insurance?[5]

More… ↓

⤷  Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.